Compare Gap Inc (GAP) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Novartis AG — how do they compare? Gap Inc trades at $23.15 (market cap $8.21B), while Novartis AG trades at $142.94 (market cap $268.57B). The key difference: Novartis AG is far larger — about 32.7× Gap Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Novartis AG for 82 Days on average.
| GAP | NVS | |
|---|---|---|
Market Cap | $8.21B | $268.57B |
Volume | 5,192,917 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $168.62 |
52-Week Low | $18.35 | $121.80 |
Typical Hold Time | 37 Days | 82 Days |
Enterprise Value | $11.44B | $309.89B |
Dividend Yield | 3% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The stock shows strong fundamentals with a low P/E of 7.04, robust ROE of 33.78%, and net income margin expansion to 8.14% in 2025. Recent earnings beats in Q1 and Q2 2026 and strategic moves into music partnerships signal brand revitalization efforts.
The outlook is positive given undervaluation, earnings momentum, and strategic initiatives, but risks include reliance on Old Navy's turnaround and competitive pressures. Upside to the price target offers potential, supported by institutional buying interest and solid cash flow generation.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
